PCSK9 inhibition in PAD

被引：4
|
作者：
Huynh, Karina
机构：
来源：
NATURE REVIEWS CARDIOLOGY | 2018年 / 15卷 / 01期
关键词：
D O I：
10.1038/nrcardio.2017.204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4 / 5
页数：1
相关论文
共 50 条
  • [41] PCSK9 inhibition in high-risk patients
    Zijlstra, Laurien E.
    Mooijaart, Simon P.
    Jukema, J. Wouter
    AGING-US, 2019, 11 (23): : 10791 - 10792
  • [42] PCSK9 inhibition and diabetes: turning to Mendel for clues
    Lee, Jooho
    Hegele, Robert A.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (02): : 78 - 79
  • [43] Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia
    Stawowy, Philipp
    Just, Isabell A.
    Kaschina, Elena
    CORONARY ARTERY DISEASE, 2014, 25 (04) : 353 - 359
  • [44] PCSK9 Inhibition: Does Lipoprotein Size Matter?
    Si-Tayeb, Karim
    Cariou, Bertrand
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (11):
  • [45] PCSK9 INHIBITION IN AN IMMATURE MURINE MODEL OF SEPSIS
    Atreya, Mihir R.
    Wong, Hector R.
    SHOCK, 2019, 51 (06): : 53 - 54
  • [46] PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
    Blom, Dirk J.
    Dent, Ricardo
    Castro, Rita C.
    Toth, Peter P.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 185 - 197
  • [47] PCSK9 inhibition: ready for prime time in CKD?
    Mafham, Marion
    Haynes, Richard
    KIDNEY INTERNATIONAL, 2018, 93 (06) : 1267 - 1269
  • [48] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
    De Stefano, D.
    Baragetti, A.
    Baragetti, A.
    Macri, N.
    Tavori, H.
    Fazio, S.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2018, 275 : E101 - E101
  • [49] DYSLIPIDAEMIA Predicting the benefits and risks of PCSK9 inhibition
    Holmes, David
    NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (02) : 65 - 65
  • [50] Inhibition of PCSK9 as a Novel Strategy for the Treatment of Hypercholesterolemia
    Lopez, Dayami
    DRUG NEWS & PERSPECTIVES, 2008, 21 (06) : 323 - 330
12345